Collecting tumor samples from triple-negative breast cancer patients to explore new treatments and biomarkers.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a collection of ex vivo tumor organoids from patients with triple-negative breast cancer. By utilizing advanced 3D cell culture techniques, the study will create organoid models that closely mimic the original tumors, allowing for the evaluation of innovative therapies and the identification of predictive biomarkers for treatment response. The organoids will be derived from patients undergoing neoadjuvant chemotherapy and will be analyzed for their growth and response to various treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient over 18 years of age
* Patient with early stage (I-III) triple negative breast cancer who needs to have clips placed before neoadjuvant chemotherapy
* Patient affiliated to a social security system
* Proficiency in French language,
* Patient having signed the consent to participate in the study.

Exclusion Criteria:

* Pregnant women
* Persons deprived of liberty or under guardianship (including curatorship)
* History of any other clinically active malignancy in the last 5 years prior to inclusion

Where it's running

• Centre François Baclesse
  Caen, France Recruiting

Study contacts

• Study coordinator: George EMILE, MD
• Email: g.emile@baclesse.unicancer.fr
• Phone: +33 2 31 45 50 50

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Organoid Drug Sensitivity-Guided Therapy for Refractory Tumors

  This study tests whether tumor organoids created from a patient’s tissue can help doctors pick drugs for adults with hard‑to-treat, unresectable, or metastatic cancers after standard options have been exhausted.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07906301

• Pre-Treatment Breast DCE-MRI AI Model to Predict Benefit from Neoadjuvant Chemo in Locally Advanced Triple-Negative Breast Cancer

  This study tests an AI model using pre-treatment breast MRI to see if it can identify which locally advanced triple-negative breast cancer patients will benefit most from neoadjuvant chemotherapy.

  Recruiting Fujian Cancer Hospital · Fuzhou, Fujian and 4 other locations · NCT07880600

• JS212-based therapy for recurrent/metastatic TNBC: as monotherapy or with partners

  This phase 2 study tests JS212 alone or with JS207 or JS001 to see if it helps people with recurrent or metastatic triple-negative breast cancer.

  Recruiting Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality and 30 other locations · NCT07876557

• Duodenal organoids to study how the gut lining interacts with pathogens

  Researchers are using tissue from patients who have part of their duodenum removed to grow living 3D organoids and test how the intestinal epithelium responds to pathogens in the lab.

  Recruiting IRCCS Sacro Cuore Don Calabria di Negrar · Negrar, Verona · NCT07828665

• Imaging study of [68Ga]Ga-DWJ155 in adults with solid tumors

  This trial tests a new radioligand imaging agent, [68Ga]Ga-DWJ155, to see how well it images tumors and how safe it is in adults with advanced solid cancers.

  Recruiting at 2 sites Phase 1 Novartis · Darlinghurst, New South Wales and 1 other locations · NCT07801508

• Can older adults with breast cancer tolerate a dense CMF chemo schedule

  This study tests whether giving a condensed CMF chemotherapy regimen is feasible for people 70 and older with breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07768436

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.